DEA review
This article was originally published in The Rose Sheet
Executive Summary
National Toxicology Program is soliciting final public comment on diethanolamine as part of 11th Report on Carcinogens review process, agency says in Jan. 22 1Federal Register notice. Comments are due within 60 days of notice. NTP Executive Committee will be making final recommendations to list, delist or not to list ingredients in the RoC. NTP Board of Scientific Counselors RoC Subcommittee recommended in November that DEA not be included in the upcoming report slated for publication in 2004 (2"The Rose Sheet" Nov. 25, 2002, p. 5)...
You may also be interested in...
DEA Exclusion From 11th Report On Carcinogens Advised By NTP Panel
Existing data suggesting diethanolamine may pose a safety risk do not meet National Toxicology Program criteria to be designated a possible human carcinogen, an NTP Board of Scientific Counselors subcommittee concluded at a meeting in Bethesda, Md. Nov. 19
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.